Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts

Clinical and Experimental Immunology

Volumn 173, Issue 2, 2013, Pages 323-331

  Takahashi, K ^a   Imaeda, H ^b   Fujimoto, T ^a   Ban, H ^b   Bamba, S ^b   Tsujikawa, T ^b   Sasaki, M ^b   Fujiyama, Y ^b   Andoh, A ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

eosinophil; IBD; SOCS; STAT

Indexed keywords

EOTAXIN 3; GAMMA INTERFERON; INTERLEUKIN 3; INTERLEUKIN 4; MESSENGER RNA; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TH2 CELL; ULCERATIVE COLITIS;

EOSINOPHIL; IBD; SOCS; STAT;

CELLS, CULTURED; CHEMOKINES, CC; COLON; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MYOFIBROBLASTS; RECEPTORS, CCR3; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TH2 CELLS; UP-REGULATION;

EID: 84880011633     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12117     Document Type: Article

References (35)

1. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010; 45:9-16.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
3. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008; 43:1-17.
4. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407.
5. Andoh A, Imaeda H, Aomatsu T etal. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011; 46:479-486.
6. Andoh A, Kuzuoka H, Tsujikawa T etal. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol 2012; 47:1298-1307.
7. Franke A, McGovern DP, Barrett JC etal. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42:1118-1125.
8. Asano K, Matsushita T, Umeno J etal. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet 2009; 41:1325-1329.
9. Kobori A, Yagi Y, Imaeda H etal. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010; 45:999-1007.
10. Lampinen M, Ronnblom A, Amin K etal. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005; 54:1714-1720.
11. Blom K, Rubin J, Halfvarson J etal. Eosinophil associated genes in the inflammatory bowel disease 4 region: correlation to inflammatory bowel disease revealed. World J Gastroenterol 2012; 18:6409-6419.
12. Coppi LC, Thomazzi SM, de Ayrizono ML etal. Comparative study of eosinophil chemotaxis, adhesion, and degranulation in vitro in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2007; 13:211-218.
13. Masterson JC, McNamee EN, Jedlicka P etal. CCR3 blockade attenuates eosinophilic ileitis and associated remodeling. Am J Pathol 2011; 179:2302-2314.
14. Lampinen M, Backman M, Winqvist O etal. Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis. J Leukoc Biol 2008; 84:1392-1399.
15. Berstad A, Borkje B, Riedel B, Elsayed S. Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology 1993; 40:276-278.
16. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14:5584-5589; discussion 8.
17. Carlson M, Raab Y, Peterson C, Hallgren R, Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999; 94:1876-1883.
18. Stubbs VE, Power C, Patel KD. Regulation of eotaxin-3/CCL26 expression in human monocytic cells. Immunology 2010; 130:74-82.
19. De Lucca GV. Recent developments in CCR3 antagonists. Curr Opin Drug Discov Devel 2006; 9:516-524.
20. Hebenstreit D, Luft P, Schmiedlechner A, Duschl A, Horejs-Hoeck J. SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol 2005; 42:295-303.
21. Hoeck J, Woisetschlager M. Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6. J Immunol 2001; 167:3216-3222.
22. Nakayama T, Watanabe Y, Oiso N etal. Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. J Immunol 2010; 185:6472-6479.
23. Mahida YR, Beltinger J, Makh S etal. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol 1997; 273:G1341-1348.
24. Okuno T, Andoh A, Bamba S etal. Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 2002; 37:317-324.
25. Dharmsathaphorn K, McRoberts JA, Mandel KG, Tisdale LD, Masui H. A human colonic tumor cell line that maintains vectorial electrolyte transport. Am J Physiol 1984; 246:G204-208.
26. Shimada M, Andoh A, Hata K etal. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol 2002; 168:861-868.
27. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000; 105:1063-1070.
28. Ohshima M, Yokoyama A, Ohnishi H etal. Overexpression of suppressor of cytokine signalling-5 augments eosinophilic airway inflammation in mice. Clin Exp Allergy 2007; 37:735-742.
29. Fuss IJ. Is the Th1/Th2 paradigm of immune regulation applicable to IBD? Inflamm Bowel Dis 2008; 14 (Suppl. 2):S110-112.
30. Darnell JE, Jr, Kerr IM, Jak SGR. STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-1421.
31. Manousou P, Kolios G, Valatas V etal. Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in-vitro studies. Clin Exp Immunol 2010; 162:337-347.
32. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 1996; 110:1683-1695.
33. Chinen T, Kobayashi T, Ogata H etal. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterology 2006; 130:373-388.
34. Heller F, Florian P, Bojarski C etal. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129:550-564.
35. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4:1169-1176.